US EditionIQVIA Releases “Global Use of Medicines Outlook Through 2029” Report
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.4 Articles
4 Articles
Over 70% of the 956 people tested under the Caravan "Health comes to you" - the edition of IV has diabetes, hypertension, high cholesterol or obesity.
Ciloa secures €6.5m from French government to advance obesity and T2 diabetes therapy - Pharmafile
French biotech company, Ciloa, has received €6.5m in funding through France 2030 to advance its lead candidate, APN-sEV, targeting obesity and type 2 (T2) diabetes. The therapy, based on stable and functional adiponectin combined with exosomes, is the world’s first recombinant form of adiponectin for metabolic diseases. Adiponectin is a hormone often referred to as […] The post Ciloa secures €6.5m from French government to advance obesity and T2…
Ciloa SAS secures €6.5m to advance lead candidate APN-sEV into clinical development - European Biotechnology Magazine
French biotech Ciloa SAS has received a €6.5m grant to advance its adiponectin-loaded exosome candidate, APN-sEV, into Phase I safety trials, ahead of efficacy evaluation in indications including type 2 diabetes, obesity, and liver fibrosis. The post Ciloa SAS secures €6.5m to advance lead candidate APN-sEV into clinical development appeared first on European Biotechnology Magazine.
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
